



# SAFETY DATA SHEET

Revision date: 06-Mar-2015

Version: 4.0

Page 1 of 9

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Donepezil Hydrochloride Orally Disintegrating Tablets

**Trade Name:** ARICEPT ODT; ARICEPT D; ARICEPT RDT; ARICEPT OROTAB; ARICEPT EVESS

**Chemical Family:** Mixture

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product for the treatment of Alzheimer's disease

### Details of the Supplier of the Safety Data Sheet

Pfizer Inc  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-800-879-3477

Pfizer Ltd  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161  
Emergency telephone number:  
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:  
CHEMTREC (24 hours): 1-800-424-9300  
Contact E-Mail: pfizer-MSDS@pfizer.com

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Acute Oral Toxicity: Category 4

#### EU Classification:

EU Indication of danger: Harmful

EU Risk Phrases:

R22 - Harmful if swallowed.

### Label Elements

**Signal Word:** Warning

**Hazard Statements:** H302 - Harmful if swallowed

#### Precautionary Statements:

P264 - Wash hands thoroughly after handling  
P270 - Do not eat, drink or smoke when using this product  
P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell  
P330 - Rinse mouth  
P501 - Dispose of contents/container in accordance with all local and national regulations

# SAFETY DATA SHEET

Material Name: Donepezil Hydrochloride Orally Disintegrating  
Tablets  
Revision date: 06-Mar-2015

Page 2 of 9

Version: 4.0



## Other Hazards

No data available

## Australian Hazard Classification (NOHSC):

Hazardous Substance. Non-Dangerous Goods.

## Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## 3. COMPOSITION / INFORMATION ON INGREDIENTS

### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Donepezil hydrochloride	120011-70-3	Not Listed	T;R25 Xi;R36	Acute Tox.3 (H301) Eye Irrit.2A (H319)	5 or 10 ***
Colloidal silicon dioxide	7631-86-9	231-545-4	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Mannitol	69-65-8	200-711-8	Not Listed	Not Listed	*
Carrageenan	9000-07-1	232-524-2	Not Listed	Not Listed	*
Ferric oxide yellow	51274-00-1	257-098-5	Not Listed	Not Listed	*
Polyvinyl alcohol	9002-89-5	Not Listed	Not Listed	Not Listed	*

### Additional Information:

\* Proprietary

\*\*\* per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

## 4. FIRST AID MEASURES

### Description of First Aid Measures

#### Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

#### Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

## SAFETY DATA SHEET

Material Name: Donepezil Hydrochloride Orally Disintegrating  
Tablets  
Revision date: 06-Mar-2015

Page 3 of 9

Version: 4.0

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:** None known

### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** None

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.

**Fire / Explosion Hazards:** Not applicable

### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical drug product

## SAFETY DATA SHEET

Material Name: Donepezil Hydrochloride Orally Disintegrating  
Tablets  
Revision date: 06-Mar-2015

Page 4 of 9

Version: 4.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Donepezil hydrochloride

Pfizer OEL TWA-8 Hr: 150µg/m<sup>3</sup>

#### Colloidal silicon dioxide

Australia TWA	2 mg/m <sup>3</sup>
Austria OEL - MAKs	4 mg/m <sup>3</sup>
	0.3 mg/m <sup>3</sup>
Czech Republic OEL - TWA	0.1 mg/m <sup>3</sup>
	4.0 mg/m <sup>3</sup>
Estonia OEL - TWA	2 mg/m <sup>3</sup>
Finland OEL - TWA	5 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	4 mg/m <sup>3</sup>
Germany (DFG) - MAK	4 mg/m <sup>3</sup>
Ireland OEL - TWAs	6 mg/m <sup>3</sup>
	2.4 mg/m <sup>3</sup>
Latvia OEL - TWA	1 mg/m <sup>3</sup>
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
	Listed
Slovakia OEL - TWA	4.0 mg/m <sup>3</sup>
Switzerland OEL - TWAs	4 mg/m <sup>3</sup>
	0.3 mg/m <sup>3</sup>

#### Analytical Method:

Analytical method available for Donepezil Hydrochloride. Contact Pfizer Inc for further information.

#### Exposure Controls

##### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

##### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

##### Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

##### Eyes:

Wear safety glasses or goggles if eye contact is possible.

##### Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

##### Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

#### Physical State:

Tablets

#### Color:

White

#### Odor:

No data available.

#### Odor Threshold:

No data available.

#### Molecular Formula:

Mixture

#### Molecular Weight:

Mixture

#### Solvent Solubility:

No data available

#### Water Solubility:

No data available

#### pH:

No data available.

## SAFETY DATA SHEET

Material Name: Donepezil Hydrochloride Orally Disintegrating  
Tablets  
Revision date: 06-Mar-2015

Page 5 of 9

Version: 4.0

### 9. PHYSICAL AND CHEMICAL PROPERTIES

**Melting/Freezing Point (°C):** No data available  
**Boiling Point (°C):** No data available.  
**Partition Coefficient: (Method, pH, Endpoint, Value)**  
**Mannitol**  
No data available  
**Carrageenan**  
No data available  
**Colloidal silicon dioxide**  
No data available  
**Polyvinyl alcohol**  
No data available  
**Ferric oxide yellow**  
No data available  
**Donepezil hydrochloride**  
Predicted 7.4 Log D 4.14  
**Decomposition Temperature (°C):** No data available.  
**Evaporation Rate (Gram/s):** No data available  
**Vapor Pressure (kPa):** No data available  
**Vapor Density (g/ml):** No data available  
**Relative Density:** No data available  
**Viscosity:** No data available

#### Flammability:

<b>Autoignition Temperature (Solid) (°C):</b>	No data available
<b>Flammability (Solids):</b>	No data available
<b>Flash Point (Liquid) (°C):</b>	No data available
<b>Upper Explosive Limits (Liquid) (% by Vol.):</b>	No data available
<b>Lower Explosive Limits (Liquid) (% by Vol.):</b>	No data available

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available  
**Chemical Stability:** Stable under normal conditions of use.  
**Possibility of Hazardous Reactions**  
**Oxidizing Properties:** No data available  
**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.  
**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers  
**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.  
**Known Clinical Effects:** Ingestion of this material can cause effects similar to those seen in clinical use including cholinergic crisis, characterized by severe nausea, vomiting, salivation, sweating, slow heart rate, low blood pressure, muscles weakness, respiratory depression, syncope and convulsions.

#### Acute Toxicity: (Species, Route, End Point, Dose)

## SAFETY DATA SHEET

Material Name: Donepezil Hydrochloride Orally Disintegrating  
Tablets  
Revision date: 06-Mar-2015

Page 6 of 9

Version: 4.0

### 11. TOXICOLOGICAL INFORMATION

#### Mannitol

Rat Oral LD50 13500 mg/kg  
Mouse Oral LD50 22 g/kg

#### Donepezil hydrochloride

Rat Oral LD50 32.6 mg/kg  
Mouse Oral LD50 45.2mg/kg  
Rat Intravenous LD50 7.6mg/kg  
Mouse Intravenous LD50 3.7mg/kg

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Donepezil hydrochloride

Eye Irritation Rabbit Irritant  
Skin Irritation Rabbit Non-irritating

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### Donepezil hydrochloride

13 Week(s) Rat Oral 1 mg/kg/day NOEL None identified  
13 Week(s) Dog Oral 1 mg/kg/day NOEL Central Nervous System  
12 Month(s) Rat Oral 3 mg/kg/day NOEL Central Nervous System  
12 Month(s) Dog Oral 5 mg/kg/day NOEL Central Nervous System

#### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

##### Donepezil hydrochloride

Embryo / Fetal Development Rat Oral 1 mg/kg/day NOEL Maternal toxicity, Not teratogenic  
Embryo / Fetal Development Rabbit Oral 3 mg/kg/day NOEL Maternal Toxicity, Not Teratogenic

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### Donepezil hydrochloride

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative  
*In Vitro* Chromosome Aberration Chinese Hamster Ovary (CHO) cells Positive  
*In Vivo* Micronucleus Mouse Negative

#### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

##### Donepezil hydrochloride

88 Week(s) Mouse No route specified 180 mg/kg/day NOEL Not carcinogenic  
104 Week(s) Rat No route specified 30 mg/kg/day NOEL Not carcinogenic

#### Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

#### Carrageenan

IARC: Group 3 (Not Classifiable)

#### Colloidal silicon dioxide

## SAFETY DATA SHEET

Material Name: Donepezil Hydrochloride Orally Disintegrating  
Tablets  
Revision date: 06-Mar-2015

Page 7 of 9

Version: 4.0

### 11. TOXICOLOGICAL INFORMATION

IARC: Group 3 (Not Classifiable)

Polyvinyl alcohol

IARC: Group 3 (Not Classifiable)

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

**Toxicity:** No data available

**Persistence and Degradability:** No data available

**Bio-accumulative Potential:**

**Partition Coefficient: (Method, pH, Endpoint, Value)**

**Donepezil hydrochloride**

Predicted 7.4 Log D 4.14

**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

# SAFETY DATA SHEET

Material Name: Donepezil Hydrochloride Orally Disintegrating  
Tablets  
Revision date: 06-Mar-2015

Page 8 of 9

Version: 4.0

## 15. REGULATORY INFORMATION

### Canada - WHMIS: Classifications

#### WHMIS hazard class:

Class D, Division 1, Subdivision A

Class D, Division 2, Subdivision B



#### Donepezil hydrochloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

#### Mannitol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-711-8

#### Carrageenan

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-524-2

#### Colloidal silicon dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-545-4

#### Ferric oxide yellow

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	257-098-5

#### Polyvinyl alcohol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed



## SAFETY DATA SHEET

**Material Name: Donepezil Hydrochloride Orally Disintegrating  
Tablets**  
Revision date: 06-Mar-2015

Page 9 of 9

Version: 4.0

### 15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

### 16. OTHER INFORMATION

#### Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed  
Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation

T - Toxic  
Xi - Irritant

R25 - Toxic if swallowed.  
R36 - Irritating to eyes.

**Data Sources:** Pfizer proprietary drug development information.

**Reasons for Revision:** Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 15 - Regulatory Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

**Revision date:** 06-Mar-2015  
Product Stewardship Hazard Communication

**Prepared by:** Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**